Acquired Immunodeficiency Syndrome (AIDS) Market Report 2026

The acquired immunodeficiency syndrome (aids) market size has grown strongly in recent years. It will grow from $33.75 billion in 2025 to $35.53 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to high prevalence of hiv infections worldwide, increasing awareness and screening programs, government-funded hiv treatment initiatives, availability of first-generation antiretroviral drugs, rising incidence of opportunistic infections.

The acquired immunodeficiency syndrome (aids) market size is expected to see strong growth in the next few years. It will grow to $43.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to development of next-generation antiretroviral therapies, expansion of prep and pep programs, growth in hiv vaccine research, adoption of digital health monitoring solutions, increasing public-private partnerships for hiv management. Major trends in the forecast period include increasing adoption of antiretroviral therapy (art), rising use of pre-exposure prophylaxis (prep) and post-exposure prophylaxis (pep), expansion of hiv diagnostic and surveillance programs, growing focus on hiv vaccine research and development, integration of hospital and retail pharmacy services.

The increasing rates of HIV infections are expected to drive the growth of the acquired immunodeficiency syndrome (AIDS) market in the coming years. HIV infections are caused by the human immunodeficiency virus (HIV), which attacks the immune system and weakens the body’s ability to fight infections and diseases. The rise in HIV infections is attributed to unprotected sexual contact with an infected individual, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and a weakened immune system or existing sexually transmitted infections. Management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infections by enabling early diagnosis, expanding access to effective antiretroviral therapies, improving prevention strategies, and strengthening healthcare systems to better control the spread of the virus. For instance, in November 2024, data from the European Centre for Disease Prevention and Control (ECDC), a Sweden-based EU agency, reported a total of 112,883 HIV diagnoses in 2023 across 47 of 53 countries in the region, including 24,731 cases in the European Union/European Economic Area (EU/EEA). The overall crude rate of HIV diagnoses was 12.7 per 100,000 population, reflecting a 2.4% increase from the 12.4 per 100,000 rate recorded in 2022. Therefore, rising HIV infections are contributing to the growth of the acquired immunodeficiency syndrome (AIDS) market.

Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are focusing on developing innovative therapies such as long-acting injectables, which improve patient adherence, reduce dosing frequency, and provide a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications administered via injection that release active ingredients gradually over an extended period, allowing less frequent dosing compared to traditional oral medications. For instance, in January 2025, GSK plc, a UK-based pharmaceutical company, announced European Commission approval for the long-acting injectable treatment Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for adolescents aged 12 years and older living with HIV and is administered via intramuscular injection every one or two months, depending on the treatment plan. The long-acting nature of the injections may improve adherence among adolescents who struggle with daily pill regimens.

In November 2024, Gilead Sciences Inc., a US-based biopharmaceutical company, acquired investigational assets related to the HTI therapeutic HIV vaccine from AELIX Therapeutics for an undisclosed amount. Through this acquisition, Gilead Sciences aims to strengthen its HIV treatment portfolio by leveraging AELIX Therapeutics’ investigational HTI therapeutic HIV vaccine to advance research in functional HIV cures and potentially reduce the need for lifelong antiretroviral therapy. AELIX Therapeutics is a Spain-based company that develops treatments and vaccines for acquired immunodeficiency syndrome (AIDS).

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare.

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acquired immunodeficiency syndrome (aids) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the aids market by increasing the cost of imported antiretroviral drugs, diagnostic kits, and medical devices essential for hiv management. Segments such as nucleoside-analog and non-nucleoside reverse transcriptase inhibitors, as well as diagnostic tests, are most affected, particularly in regions like north america, europe, and asia-pacific that rely on imports. While tariffs increase treatment costs and supply chain challenges, they have also promoted local manufacturing, domestic production capacity, and innovation in hiv treatment and prevention strategies.

The acquired immunodeficiency syndrome (aids) market research report is one of a series of new reports that provides acquired immunodeficiency syndrome (aids) market statistics, including acquired immunodeficiency syndrome (aids) industry global market size, regional shares, competitors with a acquired immunodeficiency syndrome (aids) market share, detailed acquired immunodeficiency syndrome (aids) market segments, market trends and opportunities, and any further data you may need to thrive in the acquired immunodeficiency syndrome (aids) industry. This acquired immunodeficiency syndrome (aids) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by destroying CD4 T cells, making the body susceptible to opportunistic infections, severe illnesses, and certain cancers if effective antiretroviral treatment is not administered. Management involves a combination of antiretroviral therapy (ART), regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to enhance patient outcomes and quality of life.

The main types of acquired immunodeficiency syndrome (AIDS) are human immunodeficiency virus 1 (HIV-1) and human immunodeficiency virus 2 (HIV-2). HIV-1 is a retrovirus that primarily targets the immune system by infecting CD4+ T cells, causing progressive immunodeficiency and, if untreated, the development of AIDS. The drug types include nucleoside-analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, protease inhibitors, integrase inhibitors, and pre-exposure and post-exposure prophylaxis. These drugs are administered orally or parenterally and are used in applications such as hospital pharmacies, retail pharmacies, and others, distributed through both offline and online channels.

The acquired immunodeficiency syndrome (AIDS) market consists of sales of products such as long-acting injectable antiretrovirals, broadly neutralizing antibodies (bNAbs), therapeutic HIV vaccines, latency-reversing agents, capsid inhibitors, attachment inhibitors, maturation inhibitors, and pharmacokinetic enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.